**CT angiogram negative perimesencephalic subarachnoid haemorrhage: Is a subsequent DSA necessary? A systematic review**

**Authors and affiliations:**

Midhun Mohan 1\*, ORCID ID: 0000-0002-1865-8623

Abdurrahman I. Islim 2, 3\*, ORCID ID: 0000-0001-9621-043X

Louise Dulhanty 1, ORCID ID: 0000-0003-2995-1187

Adrian Parry-Jones 1, 4, ORCID ID: 0000-0002-4462-3846

Hiren C. Patel 1, 4, ORCID ID: 0000-0002-1439-8801

**\*These authors contributed equally to the manuscript**

1 Greater Manchester Neurosciences Centre, Salford Royal Foundation NHS Trust, Stott Lane, Salford, M6 8HD

2 Institute of Translational Medicine, University of Liverpool, Liverpool, UK

3 Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK

4 Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, M13 9PT.

**Correspondence**:

Mr Hiren C Patel

Greater Manchester Neurosciences Centre

Salford Royal Foundation NHS Trust

Salford

M6 8HD, UK

Email: [hiren.patel@srft.nhs.uk](mailto:hiren.patel@srft.nhs.uk)

Tel: +44 (0)161 206 8548

**Word Count:** 2666

# **ABSTRACT**

## **Background**

Perimesencephalic subarachnoid haemorrhage (PMSAH) is a benign subtype with distinct clinical-radiological features. Digital subtraction angiography (DSA) remains the gold standard investigation for exclusion of a macrovascular cause, although increasingly more clinicians rely solely on computed tomography angiography (CTA). The primary aim of this systematic review was to evaluate the current literature regarding the negative predictive value of CTA.

## **Methods**

A systematic search in concordance with the PRISMA checklist was performed for studies published between 2000 and 2018. Studies with ≥10 adult patients diagnosed on a non-contrast brain CT with a PMSAH, who underwent a negative CTA and were subsequently subject to a DSA, were included. Simple pooled analysis was performed to inform thenegative predictive value (95% CI) of CTA and risk of DSA- and CTA-related complications.

## **Results**

Eighteen studies (669 patients) were included. All patients were subject to at least one DSA; first one mostly performed within 24 hours of CTA (68.6%). 144 (21.5%) patients underwent a 2nd DSA and a 3rd repeat DSA was performed in one patient. The overall negative predictive value of CTA was 99.0% (95% CI 97.8–99.5). The risk of complications following DSA and CTA were 1.35% (3/222) and 0% (0/41) respectively.

## **Conclusions**

Undertaking a DSA after a negative CTA may not add any further diagnostic value in patients with perimesencephalic subarachnoid haemorrhage and may lead to net harm. This observation needs to be validated in a large-scale prospective multi-centre study with complete case ascertainment and robust data on CTA and DSA complications.

**Key words**: Computed tomography angiography**;** Digital subtraction angiography; Perimesencephalic; Subarachnoid haemorrhage; Systematic review.

# **INTRODUCTION**

Most spontaneous non-traumatic subarachnoid haemorrhage (SAH) is of aneurysmal origin, however, approximately 15% have no discernable cause diagnosed on initial vascular imaging.1 Of these, 30-60% have a perimesencephalic (PMSAH) pattern of bleed, which is recognised as a distinct clinical entity of SAH, with a benign natural history.2 3

Although there has been some debate about the anatomical definition of PMSAH, its radiographic pattern on timely computed tomography (CT) is relatively distinct with haemorrhage confined anterior to the midbrain or pons. The definition of PMSAH also allows for the extension of blood into the suprasellar cistern or basal portion of the sylvian fissures and intraventricular blood, although requires the absence of frank intraventricular or intraparenchymal haemorrhage.4 5

Currently, the gold standard investigation for diagnosing a vascular lesion responsible for SAH is a digital subtraction angiography (DSA).6 However, the risk of DSA-related complications, including persistent neurological deficits is non-negligible, and has been reported to be as high as 14%.7 8 Typically, patients with PMSAH are not neurologically obtunded, have early symptom resolution, and rarely have a vascular cause identified on DSA.2 3 Because of the high risk of morbidity and mortality associated with a missed macrovascular cause, particularly posterior circulation aneurysms,5 9 imaging techniques that are specific, sensitive and non-invasive are essential.

Neurovascular imaging techniques have evolved significantly over the last two decades and the availability of computed tomography angiography (CTA) means that macrovascular causes of brain haemorrhage can be identified without a DSA.10 11

The primary aim of this systematic review was to determine the value of performing a DSA in PMSAH patients that were not found to have a vascular cause of bleed on initial CTA. The secondary aim was to compare the complication risks of CTA and DSA.

# **METHODS**

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement,12 and has been registered with PROSPERO (CRD42016032349).

## **Definitions**

The following definitions were used throughout this review:

* Patients with a perimesencephalic SAH pattern of bleed were referred to as PMSAH patients.
* PMSAH patients who underwent a CTA as the first vascular investigation and were found to have no cause to explain the bleed, were termed as CTA-negative PMSAH patients.
* CTA-negative PMSAH patients who subsequently underwent a DSA and were found not to have a vascular cause of bleed, were referred to as DSA-negative PMSAH patients.

## **Search Strategy**

A literature search was performed and last updated on July 24, 2018 in:

* Embase (Ovid): 1974 to present
* Medline (Ovid): Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and 1946 to Present
* CINAHL Plus (EBSCO)
* Cochrane Library: Central Register of Controlled Trials

The search strategy used for Embase (Ovid) and Medline (Ovid) can be found in the supplementary material (**online supplementary table 1**). The search strategy was altered appropriately for use in other databases. Bibliographies of all full-text articles screened were examined for additional studies that could have met the inclusion criteria.

## **Paper selection**

The titles of all results were screened independently by two authors (M.M. and A.I.I.). Abstracts were reviewed if titles included the following terms: non-aneurysmal-, CTA negative-, perimesencephalic- or pre-truncal SAH, in combination with DSA, imaging and diagnostic studies or anything of similar construct. Full text articles were obtained for abstracts which alluded to patients being subject to both CTA and DSA. Articles identified were included upon mutual agreement. If disagreements occurred, these were discussed with a senior author (H.C.P.) until consensus was reached. Full text articles were subject to the population, intervention, comparison, outcomes and study design (PICOS) inclusion criteria outlined in **Table 1**.

|  |  |  |
| --- | --- | --- |
| **Table 1. PICOS inclusion criteria** | | |
| **Population** | Patients diagnosed on a non-contrast brain CT with a perimesencephalic SAH, who underwent a CTA and were subsequently found not to have a vascular cause to explain the initial bleed. All traumatic SAH were excluded. Patients with a poor Hunt-Hess or the World Federation of Neurosurgical Societies’ score (grades IV-V) were excluded | |
| **Intervention** | DSA | |
| **Comparator** | Not applicable | |
| **Outcomes** | **Primary** | **Secondary** |
|  | Vascular cause to explain the initial bleed missed on CTA | DSA related complications |
|  |  | CTA related complications |
| **Study design** | Retrospective and prospective cohort studies with ≥10 adult patients (≥ 16 years). | |
| Abbreviations: CTA=computed tomography angiography; DSA=digital subtraction angiography; SAH=subarachnoid haemorrhage | | |

## **Data extraction**

A pre-piloted standardised proforma (**online supplementary figure 1**) was used to extract data independently by two authors (M.M. and A.I.I.). When study cohorts comprised only a subsection with CTA-negative PMSAH patients, the following imputation approach was implemented:

* Studies in which CTA-negative PMSAH patients comprised ≥90% of the cohort, weighted averages were calculated for quantitative analysis.
* Data fields with a lower percentage were categorised as not reported.

## **Data synthesis and statistical analysis**

Negative predictive value (NPV), defined as the percentage of patients with a negative test who do not have the disease,13 was determined using the following formula:. TN True negatives. These are DSA-negative PMSAH patients. FN = False negatives. These are the CTA-negative PMSAH patients who were subsequently found to have a vascular lesion on DSA that could explain the bleed. NPV 95% CI was calculated according to the efficient-score method.14 Baseline patient demographics were expressed using descriptive statistics. Data were analysed using SPSS version 24.0 (IBM, Armonk, NY, USA).

## **Quality assessment**

All included studies were subject to quality assessment using the Quality Assessment for Diagnostic Accuracy Studies (QUADAS-2) tool (accessed using: <http://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2/>). This was independently performed by two authors (M.M. and A.I.I.). Any discrepancies were discussed with the senior author (H.C.P.) before reaching a consensus.

# **RESULTS**

## **Literature search**

The study selection process is illustrated in **Figure 1**. The total number of titles screened was 181. Of those, 108 abstracts were reviewed and 52 were subsequently excluded. Fifty-six full-text articles were assessed for eligibility and 10 of their references were also examined. The final number of articles included was 18.15-32

## **Study characteristics**

The characteristics of the 18 included studies are summarised in **Table 2**. The majority were published after 2010. Six were prospective,15 22 24-26 32 and one study was multi-centre.18 Included exams span a 20-year study period, from 1998 to 2017.

## **Patient demographics and clinical characteristics**

The overall number of CTA-negative PMSAH patients was 669 with a study specific range from 10 to 93 patients. Age was reported in 7 studies for a total of 206 (30.8%) patients. The weighted mean age was 52.8 years (SD=3.8). Eleven studies reported sex with 240 males and 172 females. Presenting Glasgow Coma Scale (GCS), available for 127 patients, was 15.

## **Initial diagnosis of PMSAH on CT brain**

Time from symptom onset or ictus to non-contrast CT ranged from 0 (day of admission) to 12 days (4 studies, 151 patients); 125 (82.8%) patients had their CT brain within 3-days of ictus. Gijn et al’s definition of a PMSAH was adopted in all studies apart from one 4 5. This study did not state the criteria they used to define PMSAH. The CT brain was interpreted and reported by two or more neuroradiologists in 96.5% (219/227 with available data) of patients.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2. Study characteristics of the 18 included articles** | | | | | | | | |
| **Study authors** | **Publication year** | **Study design** | **Setting** | **Study period** | **N. of CTA negative PMSAH patients** | **Median/mean age (yrs.)** | **Female: male** | **N of PMSAH patients examined by at least one DSA** |
| Huttner at al.15 | 2006 | Prospective | SC | 2000 - 2004 | 64 | NR | NR | 64 |
| Kershenovich et al.16 | 2006 | Retrospective | SC | 2001 - 2005 | 11 | 52.5/52.2 | 6:4 | 10 |
| Westerlaan et al.17 | 2007 | Retrospective | SC | 2003 - 2006 | 30 | NR | NR | 30 |
| Agid et al.18 | 2010 | Retrospective | MC | 2005 - 2009 | 93 | NR | NR | 93 |
| Cruz et al.19 | 2011 | Retrospective | SC | 2006 - 2010 | 41 | NR/49.9 | 17:24 | 41 |
| Pechlivanis et al.20 | 2011 | Retrospective | SC | 2002 - 2008 | 28 | NR/60.3 | 17:11 | 28 |
| Kelliny et al.21 | 2011 | Retrospective | SC | 1998 - 2007 | 19 | NR | NR | 19 |
| Delgado Almandoz et al.32 | 2012 | Prospective | SC | 2005 - 2010 | 28 | NR | 16:12 | 28 |
| MacKinnon et al.22\* | 2013 | Prospective | SC | 2003 - 2011 | 11 | NR | NR | 11 |
| Kalra et al.23 | 2014 | Retrospective | SC | 2008 - 2014 | 18 | NR/49.3 | 8:10 | 18 |
| Kumar et al.24 | 2014 | Prospective | SC | 2011 - 2013 | 20 | NR/52.5 | 6:14 | 20 |
| Germans et al.25 | 2014 | Prospective | SC | 2009 - 2012 | 53 | 52/NR | 23:30 | 52 |
| Yap et al.26 | 2015 | Prospective | SC | 2007 - 2013 | 39 | NR/NR | NR | 35 |
| Canneti et al.27 | 2015 | Retrospective | SC | 2002 - 2013 | 15 | NR/51.5 | 7:8 | 15 |
| Ramgren et al.28 | 2015 | Retrospective | SC | 2005 - 2015 | 27 | NR/NR | NR | 27 |
| Heit et al.29 | 2016 | Retrospective | SC | 2002 - 2012 | 71 | NR | NR | 71 |
| Mortimer et al.30 | 2016 | Retrospective | SC | 2006 - 2014 | 72 | NR/52.7 | 24:48 | 72 |
| Bashir et al.31† | 2018 | Retrospective | SC | 2011 - 2017 | 35 | NR/NR | 13:22 | 35 |
| Abbreviations: NR=not reported; SC=single centre; MC=multi-centre  \*Study did not specify the end date of study period. Submission date was used instead  †5 patients for whom the initial diagnostic test was not clear were excluded | | | | | | | | |

## **CTA protocol**

Time from ictus to CTA was not available for 87.4% of patients. For those with available data, the time frame ranged from 0 (day of admission) to 17 days. Time from CT to CTA was not available in all studies. Studies which reported a CTA protocol (15 studies), utilised a helical or spiral multi-detector CT scanner. Interpretation of CTA was carried out by one neuroradiologist in 51.4% (196/381 with available data) of patients. The remaining radiology was subject to dual reporting. CTA was reported prior to DSA in 167 patients.

## **First DSA protocol**

Time from CTA to first DSA ranged from 0 (occurring concurrently) to 20 days; with 68.6% (83/121 with available data) of patients having their DSA within 24 hours. DSA was performed in a biplane neuroangiography unit in 78.6% (427/543 with available data) of patients. A 4-vessel DSA was carried out in 237 (35.4%) patients, a 6-vessel DSA in 231 (34.5%) patients whereas in the remaining cohort, the data was not available. A three-dimensional rotational DSA was used in 64.3% (205/319 with available data) of patients. Dual or triple interpretation of DSA by neuroradiologists was undertaken in 72.5% (137/189 with available data) of patients.

## **Repeat 2nd and 3rd DSA protocol**

One hundred and forty-four patients underwent a 2nd DSA. Timing was reported for 51 patients, with 22 undergoing the 2nd DSA after 6 weeks of first DSA. A mean duration of 6.4 days was observed between first and 2nd DSAs in 29 patients. A 3rd repeat DSA was only carried in one patient. Timing was not reported.

## **Missed vascular abnormalities on initial CTA**

A total of 7 (1.05%) abnormalities were found on first or subsequent DSA which were not identified on initial CTA. These are summarised in **Table 3**. The overall NPV was 99.0% (95% CI 97.8 – 99.5).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Table 3. Missed vascular lesion on initial CTA found subsequently on DSA** | | | |
|  | **First DSA** | | **Second DSA** | |
|  | **Vascular lesion** | | **Vascular lesion** | |
|  | **Definite cause of bleed\*** | **Abnormalities felt not to be the cause of the bleed\*** | **Definite cause of bleed\*** | **Abnormalities felt not to be the cause of the bleed\*** |
| Cruz et al. 201119 | - | 1-mm left internal carotid artery aneurysm | **-** | **-** |
| Delgado Almandoz et al. 201232 | - | - | 2-mm aneurysm arising from a branch of the left superior cerebellar artery† | **-** |
| Heit et al. 201629 | Vasculitis | **-** | **-** | **-** |
| Right supra clinoid internal carotid artery aneurysm | **-** | **-** | **-** |
| Aneurysm (unspecified) | **-** | **-** | **-** |
| Mortimer et al. 201630 | - | Small A1 anterior cerebral artery bleb‡ | **-** | **-** |
| Non-dominant vertebral artery irregularity: atheroma or dissection† | **-** | **-** | **-** |
| Total | 4 | 2 | 1 | 0 |
| % | 0.59 | 0.29 | 0.69 | **-** |
| NPV (95% CI) | 99.4% (98.4 – 99.8) | 99.7% (98.8 – 99.9) | 99.3% (95.6 – 99.9) | **-** |
| 99.1% (98.0 – 99.6) | | **-** | **-** |
| 99.0% (97.8 – 99.5) | | | |
| Abbreviations: NPV=negative predictive value  \*As stated by study authors  †Received endovascular treatment  ‡Managed conservatively  Details regarding management strategies of other abnormalities were not available | | | | |

## **CTA- and DSA-related complications**

One study comprising 41 patients reported no complications following CTA. The remaining 17 studies did not report whether CTA complications occurred or not. A total of 811 DSAs were performed across the 18 studies included. For 222 (27.4%) DSAs with available data, 3 (1.35%) complications occurred. One patient suffered from a bilateral posterior cerebral artery infarct leading to visual loss and one patient had left vertebral artery dissection with arterial occlusion. Contrast-related nephrotoxicity was the last complication observed resulting in widespread cerebral edema, hemiparesis and coma, albeit patient recovered afterwards.

## **Quality and bias assessment**

The quality assessment results are summarised in **online supplementary figure 2**. In most studies, there was a low risk of bias regarding selection of patients. However, lack of details surrounding CTA protocols and timing of DSA following CTA raised bias issues regarding the two domains “index test” and “flow and timing”. Overall, there were no applicability concerns.

# **DISCUSSION**

## **Summary of review aims and key findings**

This systematic review set out to evaluate the value of performing a DSA in CTA-negative PMSAH patients and compare CTA and DSA complication risks.Eighteen studies were included with a total cohort of 669 patients. Seven vascular abnormalities missed on initial CTA were identified on subsequent DSA, resulting in a conservative NPV of 99%. Complications following CTA and DSA were sparsely described, albeit at a risk of 0% and 1.35% respectively.

## **Imaging protocols**

Our analysis is a contemporary pragmatic record which pooled data from multiple departments, using different types of CTA and DSA protocols. These were performed in several health care settings using primarily a unified definition of PMSAH suggesting that these data are widely applicable to the investigation of PMSAH patients.

There are a however several cautions that need to be exercised in the interpretation of these results. Patients with a poor Hunt-Hess or the World Federation of Neurosurgical Societies’ grade on presentation were excluded from our analysis. PMSAH is not only a radiological diagnosis and imaging findings need to be correlated to the clinical picture5; a poor admission status acts as an independent predictor of unfavourable outcome and warrants a management strategy similar to patients of an “aneurysmal” SAH.33 34 Of patients with appropriately defined PMSAH, a benign presenting status (GCS 15) was present in all, although a detailed breakdown was only reported in a few studies. The time between ictus and CT brain was also not well described in the studies reviewed; four studies provided details regarding the specific timing with about one fifth of patients missing the diagnostic window for PMSAH. SAH blood normally resorbs over time, and a scan at 3-days suggesting a PMSAH may well represent the residual blood from what was in fact a patient with diffuse SAH presenting in a delayed manner. We were unable to ascertain with the data available whether the delayed diagnoses were more prevalent in such patients, however we would argue that a more cautious approach should be exercised for patients scanned after 24 hours of ictus whose CT images demonstrate a perimesencephalic pattern of bleed. The diagnostic utility of CTA depends on its quality and personnel responsible for reporting. The DSA and CTA studies were all reported by a neuroradiologist, and most series confirmed their radiological findings by dual interpretation. CTA datasets are large and significant arterial pathology could be missed by a single reporter. Double reading reduces error rates, and if a move away from DSA is considered, it is not only critical that images are interpreted by experienced clinicians, but also that these images are independently assessed by two clinicians.35 Another issue that should be highlighted is that for patients subject to DSA, a significant proportion were not getting 6-vessel imaging and complete diagnostic information. This is problematic since patients undergoing such invasive procedures are at risk of complications and if performed, should at least be to completeness.

## **Missed vascular abnormalities and DSA complications risk**

We found that the probability of a DSA demonstrating any abnormality in CTA-negative PMSAH patients was approximately 10/1000. The probability of finding a macrovascular cause responsible for the haemorrhage as stated by the study authors was 7/1000. We also found that performing a DSA in PMSAH patients is not without risk and can result in serious adverse events in 14/1000 patients. If one applies one of the two miss rates against the risk of serious neurological complications identified in this study, these results suggest that DSA may not be required in patients with PMSAH, if the initial CTA is normal. The risk of DSA complications varies widely and depends on the timing of follow-up, the adopted definition and clinical setting. The risk of persistent neurological complications has been the primary focus of historic large-scale prospective studies which reported a pooled rate of approximately 0.1%.36 More recent studies similarly report a low risk but show a non-negligible rate (~4-8%) of access-site hematoma, embolic stroke, pulmonary and cardiovascular complications and long term post-procedural headache, which increases with age, comorbidity burden and performance of procedure in low patient-volume centres.8 37 38 These factors ought to be considered and conveyed to the patient; specifically, in an era of shared decision making. Economic analyses need to be also undertaken to specifically address the issue of patient transfers to specialist neuroscience units for further investigation and identification of a delayed diagnosis *versus* DSA-associated complications. Furthermore, the clinical relevance of a DSA picking up an abnormality initially missed on CTA needs to be further evaluated. Small irregularities in blood vessels, such as ‘arterial blebs’ or extremely small aneurysms may not warrant treatment, but nevertheless, could warrant radiological follow up.

Given the overall low incidence of vascular abnormalities on delayed invasive imaging in such patients, identification of risk factors of delayed diagnoses requires pooling of a large number of patients from multiple centres. Individual patient data were not available for use in analysis and therefore such inferences could not be made. Assessment of predisposing radiological and clinical features could help stratify diagnostic strategies; high-risk patients may require more comprehensive and early investigation as to facilitate early treatment of vascular abnormalities, if identified, whereas a negative high-quality CTA in low-risk patients with non-favourable DSA-related characteristics may suffice.

## **Comparisons to published systematic reviews**

In agreement with our results, a recent meta-analysis investigating the utility of repeat imaging after initial negative CTA or DSA concluded that a repeat DSA is not required in patients with PMSAH.23 Furthermore, another systematic review addressing the question of repeat imaging in patients with non-PMSAH stated that it is warranted. However, they highlighted the heterogeneity of imaging protocols, an issue replicated in this review of PMSAH patients.39

## **Study limitations**

The analysis was based mainly on retrospective studies which were largely single centre. As a result, case ascertainment could not be guaranteed. PMSAH accounts for only 6-12% of all patients presenting with a SAH. If our CTA false-negative rate is correct, each large centre treating 100 patients with SAH each year is likely to miss a relevant abnormality in two PMSAH patients every 3 years. Given this infrequent rate of presentation, it is possible that not all adverse events and delayed diagnoses are identified by retrospective studies and the true risks might be misestimated.

# **CONCLUSIONS**

In patients presenting within 72-hours of ictus with a PMSAH, as radiologically and clinically defined in this systematic review, an initial negative CTA may be sufficient in ruling out a cause for the haemorrhage and a subsequent DSA might not be required for most cases. DSA risk cannot be ignored and is likely under-reported but if opted for, patients should be appropriately counselled of the potential serious complications and the low probability of a vascular lesion being identified. Due to the poor evidence base comprising retrospective studies, the results of this review need to be validated by a large prospective multi-centre study with complete case ascertainment.

# **REFERENCES**

1. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet (London, England) 2017;**389**(10069):655-66.

2. Marquardt G, Niebauer T, Schick U, et al. Long term follow up after perimesencephalic subarachnoid haemorrhage. Journal of neurology, neurosurgery, and psychiatry 2000;**69**(1):127-30.

3. Greebe P, Rinkel GJ. Life expectancy after perimesencephalic subarachnoid hemorrhage. Stroke 2007;**38**(4):1222-4.

4. van Gijn J, van Dongen KJ, Vermeulen M, et al. Perimesencephalic hemorrhage: a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology 1985;**35**(4):493-7.

5. Rinkel GJ, Wijdicks EF, Vermeulen M, et al. Nonaneurysmal perimesencephalic subarachnoid hemorrhage: CT and MR patterns that differ from aneurysmal rupture. AJNR American journal of neuroradiology 1991;**12**(5):829-34.

6. Thaker NG, Turner JD, Cobb WS, et al. Computed tomographic angiography versus digital subtraction angiography for the postoperative detection of residual aneurysms: a single-institution series and meta-analysis. J Neurointerv Surg 2012;**4**(3):219-25.

7. Leffers AM, Wagner A. Neurologic complications of cerebral angiography. A retrospective study of complication rate and patient risk factors. Acta Radiol 2000;**41**(3):204-10.

8. Choudhri O, Schoen M, Mantha A, et al. Increased risk for complications following diagnostic cerebral angiography in older patients: Trends from the Nationwide Inpatient Sample (1999-2009). J Clin Neurosci 2016;**32**:109-14.

9. Abla AA, Wilson DA, Williamson RW, et al. The relationship between ruptured aneurysm location, subarachnoid hemorrhage clot thickness, and incidence of radiographic or symptomatic vasospasm in patients enrolled in a prospective randomized controlled trial. J Neurosurg 2014;**120**(2):391-7.

10. Hoh BL, Cheung AC, Rabinov JD, et al. Results of a prospective protocol of computed tomographic angiography in place of catheter angiography as the only diagnostic and pretreatment planning study for cerebral aneurysms by a combined neurovascular team. Neurosurgery 2004;**54**(6):1329-40; discussion 40-2.

11. Velthuis BK, Van Leeuwen MS, Witkamp TD, et al. Computerized tomography angiography in patients with subarachnoid hemorrhage: from aneurysm detection to treatment without conventional angiography. J Neurosurg 1999;**91**(5):761-7.

12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;**339**.

13. Parikh R, Mathai A, Parikh S, et al. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol 2008;**56**(1):45-50.

14. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in medicine 1998;**17**(8):857-72.

15. Huttner HB, Hartmann M, Kohrmann M, et al. Repeated digital substraction angiography after perimesencephalic subarachnoid hemorrhage? Journal of neuroradiology Journal de neuroradiologie 2006;**33**(2):87-9.

16. Kershenovich A, Rappaport ZH, Maimon S. Brain computed tomography angiographic scans as the sole diagnostic examination for excluding aneurysms in patients with perimesencephalic subarachnoid hemorrhage. Neurosurgery 2006;**59**(4):798-2.

17. Westerlaan HE, Gravendeel J, Fiore D, et al. Multislice CT angiography in the selection of patients with ruptured intracranial aneurysms suitable for clipping or coiling. Neuroradiology 2007;**49**(12):997-1007.

18. Agid R, Andersson T, Almqvist H, et al. Negative CT angiography findings in patients with spontaneous subarachnoid hemorrhage: When is digital subtraction angiography still needed? American Journal of Neuroradiology 2010;**31**(4):696-705.

19. Cruz JP, Sarma D, Noel de Tilly L. Perimesencephalic subarachnoid hemorrhage: when to stop imaging? Emergency radiology 2011;**18**(3):197-202.

20. Pechlivanis I, Shang F, Harders A, et al. Perimesencephalic hemorrhage and vessel variants. Central European neurosurgery 2011;**72**(2):78-83.

21. Kelliny M, Maeder P, Binaghi S, et al. Cerebral aneurysm exclusion by CT angiography based on subarachnoid hemorrhage pattern: a retrospective study. BMC neurology 2011;**11**:8.

22. MacKinnon AD, Clifton AG, Rich PM. Acute subarachnoid haemorrhage: is a negative CT angiogram enough? Clin Radiol 2013;**68**(3):232-8.

23. Kalra VB, Wu X, Matouk CC, et al. Use of follow-up imaging in isolated perimesencephalic subarachnoid hemorrhage: a meta-analysis. Stroke 2015;**46**(2):401-6.

24. Kumar R, Das KK, Sahu RK, et al. Angio negative spontaneous subarachnoid hemorrhage: Is repeat angiogram required in all cases? Surg Neurol Int 2014;**5**.

25. Germans MR, Coert BA, Majoie CBLM, et al. Spinal axis imaging in non-aneurysmal subarachnoid hemorrhage: a prospective cohort study. Journal of neurology 2014;**261**(11):2199-203.

26. Yap L, Dyde RA, Hodgson TJ, et al. Spontaneous subarachnoid hemorrhage and negative initial vascular imaging-should further investigation depend upon the pattern of hemorrhage on the presenting CT? Acta neurochirurgica 2015;**157**(9):1477-84.

27. Canneti B, Mosqueira AJ, Nombela F, et al. Spontaneous Subarachnoid Hemorrhage with Negative Angiography Managed in a Stroke Unit: Clinical and Prognostic Characteristics. Journal of Stroke & Cerebrovascular Diseases 2015;**24**(11):2484-90.

28. Ramgren B, Siemund R, Nilsson OG, et al. CT angiography in non-traumatic subarachnoid hemorrhage: the importance of arterial attenuation for the detection of intracranial aneurysms. Acta radiologica (Stockholm, Sweden : 1987) 2015;**56**(10):1248-55.

29. Heit JJ, Pastena GT, Nogueira RG, et al. Cerebral Angiography for Evaluation of Patients with CT Angiogram-Negative Subarachnoid Hemorrhage: An 11-Year Experience. AJNR American journal of neuroradiology 2016;**37**(2):297-304.

30. Mortimer AM, Appelman AP, Renowden SA. The negative predictive value of CT angiography in the setting of perimesencephalic subarachnoid hemorrhage. Journal of neurointerventional surgery 2016;**8**(7):728-31.

31. Bashir A, Mikkelsen R, Sorensen L, et al. Non-aneurysmal subarachnoid hemorrhage: When is a second angiography indicated? Neuroradiology Journal 2018;**31**(3):244-52.

32. Delgado Almandoz JE, Jagadeesan BD, Refai D, et al. Diagnostic Yield of Repeat Catheter Angiography in Patients With Catheter and Computed Tomography Angiography Negative Subarachnoid Hemorrhage. Neurosurgery 2012;**70**(5):1135-42.

33. Konczalla J, Platz J, Schuss P, et al. Non-aneurysmal non-traumatic subarachnoid hemorrhage: Patient characteristics, clinical outcome and prognostic factors based on a single-center experience in 125 patients. BMC Neurology 2014;**14**(1):140.

34. Tsermoulas G, Flett L, Gregson B, et al. Immediate coma and poor outcome in subarachnoid haemorrhage are independently associated with an aneurysmal origin. Clinical neurology and neurosurgery 2013;**115**(8):1362-65.

35. Lian K, Bharatha A, Aviv RI, et al. Interpretation errors in CT angiography of the head and neck and the benefit of double reading. AJNR American journal of neuroradiology 2011;**32**(11):2132-5.

36. Cloft HJ, Joseph GJ, Dion JE. Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis. Stroke 1999;**30**(2):317-20.

37. Kaufmann TJ, Huston J, 3rd, Mandrekar JN, et al. Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. Radiology 2007;**243**(3):812-9.

38. Willinsky RA, Taylor SM, TerBrugge K, et al. Neurologic complications of cerebral angiography: prospective analysis of 2,899 procedures and review of the literature. Radiology 2003;**227**(2):522-28.

39. Bakker NA, Groen RJM, Foumani M, et al. Repeat digital subtraction angiography after a negative baseline assessment in nonperimesencephalic subarachnoid hemorrhage: A pooled data meta-analysis. A systematic review. Journal of neurosurgery 2014;**120**(1):99-103.

# **DETAILS OF CONTRIBUTORS**

**M. Mohan**: study idea conception, protocol development, data collection, data analysis and manuscript writing/drafting.

**A.I. Islim**: study idea conception, protocol development, data collection, data analysis and manuscript writing/drafting.

**L. Dulhanty**: study idea conception, protocol development and manuscript writing/drafting.

**A. Parry-Jones**: study idea conception, protocol development and manuscript writing/drafting.

**H.C. Patel**: study supervision, study idea conception, protocol development and manuscript writing/revision

# **ACKNOWLEDGMENTS**

None.

# **CONFLICTS OF INTEREST**

The authors have no relevant disclosures to declare.

# **FUNDING SOURCES**

None.

# **Figure legends**

**Figure 1**. PRISMA flow chart demonstrating the study selection process

**ONLINE SUPPLEMENTARY MATERIAL**

|  |  |
| --- | --- |
| Online supplementary table 1. Search terms for Medline (Ovid) and Embase (Ovid) | |
| Date: 24/07/18 | |
| Search | Query |
| #1 | exp subarachnoid h?emorrhage/ |
| #2 | ((perimesencephalic or pretruncal or non-aneurysmal or (CT\* adj2 negative)) adj3 h?emorrhage).mp. |
| #3 | 1 and 2 |
| #4 | (DSA or digital subtraction angio\* or CTA or computed tomography angio\* or CT angio\*).mp. |
| #5 | 3 and 4 |
| #6 | limit 5 to (English language and yr="2000 -Current") |



**Online supplementary figure 1. Data collection proforma**

\\ufs02\user02\HLAISLIM\MWSDesktop\Fig3.tif

**Online supplementary figure 2. Quality assessment results**